Nerviano Medical Sciences - Part of NMS Group’s Post

Colorectal cancer takes center stage at the conference, with the majority of abstracts focused on this area. This year’s ESMO - European Society for Medical Oncology meeting concluded for the introduction of new therapeutic classes and the release of data on innovative molecules in colorectal cancer space, including Innovent Biologics’ Phase I first-in-class PD-1/IL-2 bispecific antibody fusion protein (IBI363) for advanced colorectal cancer, MSD/Inspirna, Inc.’s Phase I/II SLC6A8 inhibitor (ompenaclid) in RAS mutated mCRC, and NextCure, Inc.’s  Phase I/II LAIR-2 Fc protein (NC410) in MSS/MSI-L colorectal cancer patients. Pfizer and Amgen are also presented updates on their treatments for mutation-specific colorectal cancer, focusing on BRAF and KRAS mutations, respectively. Unlock Expert Insights and Detailed Analysis through DelveInsight Business Research LLP's Premier ESMO - European Society for Medical Oncology 2024 Coverage @ https://lnkd.in/g28ZSDJU #esmo #esmo2024 #esmoconference #conference #esmocoverage #detailedinsights #pharma #pharmaceutical

Genetron MRD is the NGS-based, tumor-informed, customized minimal residual disease (MRD) test for solid tumors exclusively co-developed by Genetron Health and AstraZeneca R&D China. It is the first MRD product co-developed by a biopharmaceutical company and a precision oncology platform company in China. The product development underwent validation with thousands of gold standard samples and additionally tested clinical tumor samples from over 30 types of solid tumors, including lung cancer, colorectal cancer, liver cancer, gastric cancer, cervical cancer, pancreatic cancer, breast cancer, prostate cancer, bladder cancer, and rhabdomyosarcoma. The performance of Genetron MRD is superior to the standards recommended by expert consensus guidelines with a limit of detection as low as 0.01%, a detection rate greater than 95% and an average sequencing depth of 80,000X-100,000X. #GenetronHealth #Cancer #NGS #Oncology #MRD #Molecularprofiling #Laboratorydevelopedtest 

Let's talk about solid tumours...   One of the key challenges facing the oncology field is finding the perfect target for treating solid tumours. This is because almost all tumour targets can also be found on healthy cells.   The result? It's very difficult to find the "perfect" target antigen in solid tumours that does not cause any on-target off-tumour toxicity.   This is where Bi-Cygni® comes in. Our solution to this tricky problem in solid tumours is to use our unique platform to help design first-in-class antibody-drug conjugates (ADCs) that can selectively target dual antigen binding events in cancer cells while leaving "non-target cells" unharmed.   We've already used this approach to create a promising Bi-Cygni® ADC for ovarian cancer, BVX002, and we hope to apply it to many more solid tumour indications in the future.   To learn more about our pipeline and our science, check out our website: https://lnkd.in/emX6WskJ   #ADC #therapeutics #oncologyresearch #solidtumors #antibodies #biotherapeutics #ovariancancer

Antibody Drug Conjugates (ADCs) are revolutionizing cancer treatment by combining monoclonal antibodies' precision with the potency of cytotoxic agents. This targeted approach delivers chemotherapy directly to cancer cells, minimizing damage to healthy tissues. Recent approvals, like trastuzumab deruxtecan for HER2-positive breast cancer, demonstrate promising clinical efficacy and safety. The continuous evolution of linker technologies and payloads is enhancing ADCs' performance, paving the way for improved treatment of hematologic malignancies and solid tumors. #CancerTreatment #ADCs #MedicalInnovation In your opinion, how will the continued development of ADCs influence the standard of care for oncology patients in the next decade?

The ESMO - European Society for Medical Oncology 2024 conference will unveil significant new findings in gastrointestinal cancers, highlighting advancements in the treatment of cervical, endometrial, and ovarian cancers. The treatment landscape for ovarian and endometrial cancers is evolving swiftly, with exciting data readouts of several novel targets. MorphoSys will present data from its Phase II trial of the EZH2/EZH1 inhibitor, tulmimetostat, targeting ARID1A-mutated ovarian clear cell carcinoma. Acrivon Therapeutics, Inc. will showcase its Phase II dual CHK1/2 inhibitor’s response, ACR-368 for ovarian and endometrial cancers. At the same time, NextCure, Inc. will reveal early results from its Phase I/II trial of the LAIR-1 fusion protein, NC410, in ovarian cancer. Eisai US’s Phase I CBP/β-catenin inhibitor, E7386’s data expected in advanced endometrial cancer, and Immunocore will present its Phase I PRAME × CD3 ImmTAC T cell engager, brenetafusp, for platinum-resistant ovarian cancer. Benefit from Expert Insights and Extensive Analysis with DelveInsight Business Research LLP's ESMO - European Society for Medical Oncology 2024 Exclusive Coverage @ https://lnkd.in/gyG_CAHU #esmo #esmo2024 #esmoconference #conference #esmocoverage #detailedinsights #pharma #pharmaceutical

For patients with NSCLC, initial use of SGT increases subsequent CGP test cancellations - Vivek Subbiah, MD OncoAlert OncoDaily ESMO - European Society for Medical Oncology #Biomarkers #Cancer #CGPTest #ELCC24 #LungCancer #NSCLC #OncoDaily #Oncology

#NeoGenomics Laboratories is partnered with ImmunoGen, Inc. on a FOLR1 testing program to provide testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients. This testing program was designed to help reduce barriers to IHC testing for novel biomarkers and aid oncologists in making informed treatment decisions for their ovarian cancer patients. Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy. To learn more about this program, the patient eligibility criteria, and to download the test requisition form, please visit: https://lnkd.in/gNxygjTB #OvarianCancer #CancerTesting #Oncology

📢 We’re proud to announce that our paper "Hyperthermia in Combination with Emerging Targeted and Immunotherapies" has been published open access in Cancers by MDPI. 🔍 The article discusses the ongoing challenge of cancer as a leading global cause of death despite advancements in therapies. Primary authors Tine Logghe and Eke van Zwol highlight the role of hyperthermia (HT) as a modality in cancer treatment, particularly its effectiveness as a sensitizer and its impact on cancer–immunity processes and oncogenic pathways. The article notes the recent focus on immunotherapy (IT) and targeted therapy (TT) in cancer research, both in academia and pharmaceutical companies. The main focus of the manuscript is to explore potential therapies that can enhance the effects of HT by targeting molecular pathways. The ultimate goal is to pave the way for future research and clinical trials, aiming to harness the synergistic potential of combining emerging IT and TT with HT for improved outcomes. Read the full article here: https://lnkd.in/ewqcUyUf #Elmedix #CancerResearch #Hyperthermia

#NeoGenomics Laboratories is partnered with ImmunoGen, Inc. on a FOLR1 testing program to provide testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients. This testing program was designed to help reduce barriers to IHC testing for novel biomarkers and aid oncologists in making informed treatment decisions for their ovarian cancer patients. Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy. To learn more about this program, the patient eligibility criteria, and to download the test requisition form, please visit: https://lnkd.in/gNxygjTB #OvarianCancer #CancerTesting #Oncology

Merck initiates Phase 3 clinical trial of MK-1084, an investigational oral KRAS G12C inhibitor, in combination with KEYTRUDA® (pembrolizumab) for first-line treatment of certain patients with metastatic non-small cell lung cancer. KRAS mutations are one of the most frequently observed mutations in human cancers, making them a crucial target for precision oncology therapy. MK-1084 is an investigational, oral covalent inhibitor of KRAS G12C, that is found in about 14% of people with non-small cell lung cancer. MK-1084 is currently under Phase 1 evaluation as monotherapy and as combined therapies in patients with KRAS G12C mutant advanced solid tumors. Chemenu supports your scientific research and drug discovery. Check our product catalog: https://lnkd.in/gnR76Fzj   #Cancer #Tumor #Lung #NSCLC #KRAS #G12C #mutations #covalent #inhibitor